Addyi Adolescent (12 to 17) Transition to Adult Care

What Is Flibanserin and Why Does Age Matter?

Flibanserin (brand name Addyi) is a non-hormonal, centrally acting agent approved by the FDA in August 2015 for acquired, generalized HSDD in premenopausal women. Its mechanism differs from hormonal therapies: flibanserin acts as a serotonin 1A agonist and serotonin 2A antagonist while also blocking dopamine D4 receptors, shifting the balance of excitatory and inhibitory neurotransmitters that regulate sexual desire. [1]

Age matters for two reasons. First, the FDA approval is age-gated at 18. Second, HSDD in adolescents involves developmental, psychological, and social factors that the adult clinical trials did not study.

The FDA Approval Label

The original NDA 022526 approved by FDA on August 18, 2015, explicitly confines the indication to premenopausal adult women. The prescribing information states: "The safety and effectiveness of ADDYI in pediatric patients have not been established." [1] That single sentence has large implications for any clinician or patient under 18 who encounters this drug.

No Pediatric Trial Data Exists

No published randomized controlled trial has enrolled patients under 18 for flibanserin. The three key Phase 3 trials, BEGONIA (N=1,378), VIOLET (N=1,463), and DAISY (N=949), enrolled adult women with a mean age in the mid-30s. [2] Extrapolating efficacy or safety from those populations to adolescents is not supported by any guideline.

Why Adolescents May Encounter This Drug Anyway

Off-label prescribing exists. An adolescent who receives a diagnosis of HSDD from a gynecologist or psychiatrist may find flibanserin mentioned in patient forums or by a provider unfamiliar with the age restriction. Transition-age youth (16 to 18) are the most common group where this ambiguity arises, making structured transition planning a clinical priority.

FDA REMS Program: What Every Transition-Age Patient Must Know

The ADDYI Risk Evaluation and Mitigation Strategy (REMS) is a mandatory safety program that applies to every prescription of flibanserin, regardless of the patient's age at the time of dispensing. Prescribers must enroll, pharmacies must certify, and patients must complete a patient-provider agreement form before each new prescription is dispensed. [1]

The Alcohol Prohibition Is Absolute

The most serious risk in the REMS is hypotension and syncope from the alcohol-flibanserin interaction. The prescribing information labels this contraindicated. In a pharmacodynamic interaction study (N=25), subjects who drank alcohol within 2 hours of flibanserin had a 13/9 mmHg additional drop in blood pressure compared with those who took flibanserin without alcohol. [1] Three of 25 subjects experienced syncope in that study.

For a 16- or 17-year-old transitioning into adult social environments where alcohol exposure rises sharply, this risk is not theoretical. The American College of Obstetricians and Gynecologists (ACOG) notes that alcohol use among adolescents aged 15 to 17 in the United States is common enough to warrant specific screening at every gynecology visit. [3]

CNS Depressants Compound the Risk

Benzodiazepines, opioids, sleep aids, antihistamines, and herbal supplements such as valerian all carry a warning in the flibanserin labeling. Adolescents prescribed medications for anxiety, ADHD, or insomnia must disclose every concurrent drug to any provider writing a flibanserin prescription.

CYP3A4 Inhibitors Are Contraindicated

Flibanserin is metabolized primarily by CYP3A4. Strong inhibitors including fluconazole (commonly prescribed for recurrent vulvovaginal candidiasis), ketoconazole, clarithromycin, and grapefruit juice can raise flibanserin plasma concentrations to dangerous levels. In a dedicated drug-interaction study, fluconazole 200 mg daily for 4 days increased flibanserin AUC by 7-fold. [1] Adolescent patients treated for fungal infections must pause flibanserin for at least 2 days before starting any azole antifungal.

Defining HSDD in the Adolescent Context

HSDD in adults is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity causing marked distress, present for at least 6 months, and not explained by another medical or psychiatric condition. [4]

Developmental Considerations

Sexual desire in adolescents follows a non-linear developmental trajectory. Studies using the Female Sexual Function Index (FSFI) show that desire domain scores in women aged 18 to 24 are measurably lower on average than in women aged 25 to 34, a pattern attributed to psychosocial development rather than pathology. [5] Applying the adult HSDD diagnostic threshold to a 16-year-old requires careful clinical judgment and is not automatically warranted.

Ruling Out Secondary Causes First

Before any pharmacologic treatment is discussed, secondary causes of low sexual desire must be excluded. These include:

• Hypothyroidism (TSH screening recommended by the American Thyroid Association at any age with symptoms)
• Hyperprolactinemia from antipsychotic medications
• Oral contraceptive-associated androgen suppression
• Depression and anxiety, which independently suppress desire
• Trauma and adverse childhood experiences

The Endocrine Society clinical practice guideline on female sexual dysfunction does not recommend flibanserin as a first-line option and specifically notes the absence of pediatric data. [6]

Psychotherapy Before Pharmacology

Cognitive behavioral therapy (CBT) and mindfulness-based sex therapy have Level I evidence in adult women with HSDD. The 2019 International Society for Sexual Medicine (ISSM) guidelines state that psychological interventions should be offered before or alongside pharmacologic treatment. [7] For adolescents, this hierarchy is even stronger given the lack of drug data.

The Transition From Pediatric to Adult Care: A Clinical Roadmap

Transition from adolescent to adult healthcare is a structured process, not a single appointment. The American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Physicians jointly published a clinical report recommending that transition planning begin no later than age 14 and that patients achieve full adult-care integration by age 22. [8]

For a patient who has been prescribed flibanserin off-label at age 17, or who is being considered for flibanserin at age 18, the transition has several specific checkpoints.

Step 1: Medication Reconciliation at Age 17.5

Every drug the adolescent takes should be reviewed against the flibanserin interaction table at least 6 months before the planned transfer to adult care. Particular attention should go to:

• Any SSRI or SNRI (moderate interaction with flibanserin, additive CNS depression possible)
• Hormonal contraceptives (no pharmacokinetic interaction, but desire effects of combined oral contraceptives should be reassessed)
• Antifungals prescribed for recurrent infections
• Any supplement containing St. John's Wort, which is a CYP3A4 inducer and may reduce flibanserin efficacy

Step 2: Re-evaluate the HSDD Diagnosis Formally at 18

The first adult-care visit is an opportunity to apply the DSM-5 criteria rigorously, without the developmental ambiguity present at 15 or 16. A validated tool, the Female Sexual Distress Scale-Revised (FSDS-R), should be administered. A score above 11 out of 48 is the accepted threshold for clinically significant distress. [5]

Step 3: Re-certify the REMS Agreement

Even if the patient was taking flibanserin before age 18 under an off-label prescription, the adult prescriber must issue a new REMS-compliant prescription. The patient-provider agreement form must be signed again. The pharmacist must re-verify REMS certification. This is not a paperwork formality: it is a safety checkpoint that ensures the alcohol warning is re-delivered by a new clinical team.

Step 4: Alcohol and Social Environment Reassessment

Turning 18 in the United States does not confer legal alcohol access (the minimum legal drinking age is 21), but it does mark a period of increased social exposure to alcohol at college, social events, and workplaces. The adult prescriber should screen using the AUDIT-C tool (a 3-question validated screen) and document the result. A score of 3 or higher in women warrants a direct conversation about whether flibanserin is appropriate to continue. [9]

Step 5: Blood Pressure and Orthostatic Vital Signs

Flibanserin's syncope risk is not limited to the alcohol interaction. Even in the absence of alcohol, approximately 0.4% of patients in the Phase 3 trials experienced syncope. [1] A baseline orthostatic blood pressure measurement (supine to standing, 1 minute and 3 minutes) should be documented at the first adult-care appointment.

Off-Label Use in Adolescents: The Regulatory and Ethical Field

Prescribing flibanserin to a patient under 18 is off-label. That is not automatically prohibited under U.S. Law: the FDA regulates drug approval, not physician prescribing practice. Off-label use is legal and common, representing an estimated 20% of all outpatient prescriptions in the United States. [10]

The Pediatric Research Equity Act Does Not Apply Here

The Pediatric Research Equity Act (PREA) requires that certain NDAs include pediatric studies. However, PREA exemptions are granted when the condition does not occur in pediatric populations, or when off-label use is not sufficiently common to warrant a formal pediatric study. The FDA has not issued a Pediatric Study Plan (PSP) requirement for flibanserin, consistent with the position that HSDD is not a recognized pediatric indication. [11]

What the REMS Means for Minor Patients

The ADDYI REMS requires that all dispensing pharmacists confirm the patient has received the medication guide. For a minor, the question of who signs the patient-provider agreement (the minor, a parent, or both) is not explicitly addressed in the REMS documentation, creating a practical ambiguity that adult-transition providers should resolve before the first prescription is written.

Informed Consent and Assent Standards

Under standard bioethical practice, a patient under 18 should provide assent to treatment even when a parent or guardian provides legal consent. The American Academy of Pediatrics policy on informed consent states that adolescents aged 14 and older have sufficient cognitive capacity to participate meaningfully in treatment decisions. [12] Any conversation about flibanserin in this age group should include a direct, age-appropriate explanation of the alcohol contraindication and the syncope risk.

Monitoring Parameters After Age 18 Initiation

Once a patient is 18 and legally prescribed flibanserin under the REMS, ongoing monitoring follows the same protocol as for any adult woman on the drug, with added attention to issues common in young adults.

Efficacy Assessment at 8 Weeks

The Phase 3 trials used 4-week recall diaries measuring satisfying sexual events (SSEs). In the pooled analysis of BEGONIA, VIOLET, and DAISY, flibanserin 100 mg nightly produced a mean increase of 0.5 additional SSEs per month above placebo at 24 weeks. [2] That modest effect size means the benefit-risk ratio should be revisited at 8 weeks. If the patient reports no subjective improvement in desire and no increase in SSEs, the drug should be discontinued.

Somnolence and Fatigue

Somnolence was reported by 11.4% of flibanserin-treated patients vs. 3.6% of placebo patients in the pooled Phase 3 data. [1] Young adults with demanding academic or work schedules may find this side effect disproportionately new. Bedtime administration is required precisely because of this effect, but early morning waking for classes or shifts may still be affected.

Mental Health Co-monitoring

HSDD and depression share overlapping neurobiology. A patient who begins flibanserin and then develops worsened mood or anxiety may be experiencing a drug effect, a natural disease course, or both. Validated depression screening with PHQ-9 at each follow-up visit provides documentation and clinical clarity.

Practical Checklist for the Transitioning Patient

Patients and caregivers preparing for adult care with flibanserin in the picture can use the following review points:

• Confirm the adult prescriber is REMS-certified before booking the first appointment
• Bring a complete medication and supplement list, including all OTC antihistamines
• Ask the new provider to document orthostatic blood pressure at baseline
• Complete the AUDIT-C screen honestly before the appointment
• Review the current patient-provider agreement form (available at the official Addyi REMS website and referenced in the FDA prescribing information) [1]
• Schedule a follow-up appointment at 8 weeks, not 3 months, to assess early efficacy
• Understand that any dental, dermatology, or urgent-care provider prescribing a fluconazole course must be told about flibanserin before the prescription is written

Special Population Considerations at Transition

Patients With a History of Anxiety or Depression

Flibanserin's serotonergic mechanism means it interacts pharmacodynamically with SSRIs and SNRIs. The ADDYI labeling states that co-administration of moderate CYP3A4 inhibitors, including some antidepressants, may increase flibanserin exposure and risk. [1] Any adolescent who has been on fluoxetine, fluvoxamine, or ciprofloxacin should have a pharmacist-level interaction review before flibanserin is initiated at 18.

Patients With Irregular Menstrual Cycles

Flibanserin is approved only for premenopausal women. Adolescents with polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, or primary ovarian insufficiency may have hormonal profiles that overlap with perimenopausal states. The prescribing information does not address this subgroup directly. A specialist in reproductive endocrinology should evaluate whether the "premenopausal" criterion is met before flibanserin is prescribed.

Patients Considering Pregnancy

Flibanserin is rated FDA Pregnancy Category not formally assigned under current labeling conventions, but the prescribing information states there are no adequate human data on use during pregnancy and that the drug should be discontinued if pregnancy occurs. [1] Transition-age patients who are sexually active and not using reliable contraception should discuss this before starting.